Overview
Can You Diagnose this Patient with Edema, Pain, Abdominal Swelling, and/or Fatigue?
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
When your patient presents with symptoms such as edema, fatigue, and abdominal pain, what might you first suspect and can you reach the right diagnosis? Put your diagnostic skills to the test! In just 15 minutes, navigate through real-world cases and upon completion, hear faculty insights on the implications of your decisions along with rationales for appropriate next steps to aid in making a final diagnosis, as well as evidence-based treatment strategies. Apply the latest scientific evidence into evolving treatment plans and improve the management of your patients today!
This educational activity is intended for allergists, immunologists, dermatologists, OB/GYNs, gastroenterologists, internists, hospitalists, primary care physicians, pediatricians, emergency physicians, and advanced practice providers (NPs and PAs) who treat both adult and pediatric patients in specialty and primary practice.
Clinicians may see few patients with rare genetic diseases. There is also enormous diversity in their clinical course and characteristics, and many early symptoms may be similar and often nonspecific. Consequently, many patients may go undiagnosed for many years, indicating the need for improved diagnosis in primary care and specialty settings. Due to the nuances and heterogeneity of these conditions as well as therapies that are now available for burdened patients, this educational course will provide clinicians with strategies to facilitate timely diagnoses and individualize therapeutic approaches.
Upon completion of this activity, learners will be able to:
• Implement evidence-based strategies to facilitate prompt and accurate diagnosis of rare and common diseases
• Evaluate safety and efficacy data of therapies based on disease
• Apply the latest scientific evidence into evolving treatment plans
• Implement evidence-based strategies to facilitate prompt and accurate diagnosis of rare and common diseases
• Evaluate safety and efficacy data of therapies based on disease
• Apply the latest scientific evidence into evolving treatment plans
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Marc Riedl, MD, MS
Professor of Medicine
University of California, San Diego
San Diego, CA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Marc Riedl, MD, MS (Faculty)
Consultant: Astria, Biocryst, Biomarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, Kalvista, Pfizer, Pharming, Pharvaris, Sanofi-Regeneron, Takeda
Grants/Research Support: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Pharvaris, Takeda
Honoraria: CSL Behring, Grifols, Pharming, Takeda
Shanthi Narla, MD (Peer Reviewer)
No financial relationships to disclose.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: tranexamic acid
This activity will take approximately 90 minutes to complete. To receive credit, learners are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
